Fidelity Life Sciences has a strong presence in the Indian Pharma Market with rising prescriptions from various specialties (Cardiac, diabetic, Gastrointestinal, Antibiotics and Multi-vitamins) through its domestic marketing division. We believe in building brands and keep introducing new products to address the growing needs of our customers.
Fidelity Life Sciences welcomes strategic partners to license-in products for the domestic market.
2011 marked a year of inspiring accomplishments, the result of our coordinated efforts to build the Fidelity of tomorrow. We are investing our resources, ideas and energies to emerge as a niche player in the branded generics business in India. In 2011, we have faced lot of challenges in establishing ourselves as one of the prominent player in cardiovascular and anti-diabetics segment in Maharashtra and we could meet those challenges to the best of our abilities. We are on expansion drive over next 2 years to be a nationwide player commanding a significant market share in this segment. Our objective to create a sustainable enterprise in the cardiovascular and diabetic branded generics segment. We would achieve this byOur strengths include
International Business has occupied a position of prominence in Fidelity’s strategy and its long term vision.Contract Manufacturing
Fidelity plans to expand its presence in semi-regulated markets and enter in advanced markets with Contract Manufacturing Services (Fidelity Magbro Life Sciences LLP).
Fidelity offers its State-of-the-Art WHO-GMP approved facilities for manufacturing of various Finished Dosage Forms for exports to Rest of the World. The manufacturing facilities hold good capacities and are managed by efficient and skilled professionals. We ensure consistent quality and timely delivery.Dosages manufactured and their annual capacities: Contract Research
Fidelity group has presence in US, UK and European market with its clinical research services (Synapse Labs Private Limited) through its State-of-the-Art approved facilities for conducting bioavailability/bioequivalence studies. We have successfully conducted more than 300 bioequivalence studies. Many studies conducted for submission of product dossiers to MHRA, EMEA, US FDA and TGA. We have expertise in conducting biostudies for critical products in ICU settings. We have more than 70 validated analytical methods for range of critical molecules, endogenous compounds, light sensitive products and have expertise in developing critical bioanalytical methods such as Iron sucrose, Ursodiol, Fesoterodine, Pyridostigmine etc.